Pharmaceuticals Financial News

Shilpa Medicare with a target price of Rs 540. The current market price of Shilpa Medicare is Rs 441.95. Shilpa Medicare Ltd., incorporated in the year 1987, is a Small Cap company (having a market cap of Rs 3828.83 Crore) operating in Pharmaceuticals sector.

In late January, Eli Lilly (NYSE:LLY) weight-loss drugs helped the Indianapolis-based drugmaker replace Tesla (NASDAQ:TSLA) from the Magnificent 7.

Name of the fundFive-year returns (in %)10-year returns (in %)ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund29.22-Mirae Asset Healthcare Fund27.55-ITI Pharma & Healthcare Fund27.15-SBI Healthcare Opportunities Fund26.6817.16Tata India Pharma & Heathcare Fund26.40- The ongoing surge in the Indian pharmaceutical sector has created wealth for investors, especially those invested in healthcare companies. Additionally, the pharmaceutical and healthcare sector serves as a defensive theme as people persist in seeking medical assistance and taking medications even during challenging times.

The category reserved for retail investors was subscribed 6 times, while that for NIIs was booked 80%.

Uttam Sugar Mills Ltd.(up 4.13%), DCM Shriram Industries Ltd.(up 3.68%), Balrampur Chini Mills Ltd.(up 3.38%), Kothari Sugars & Chemicals Ltd.(up 3.16%), Sakthi Sugars Ltd.(up 2.97%), Triveni Engineering & Industries Ltd.(up 2.62%), Bajaj Hindusthan Sugar Ltd.(up 2.61%), Rajshree Sugars & Chemicals Ltd.(up 1.78%), Mawana Sugars Ltd.(up 1.68%) and Simbhaoli Sugars Ltd.(up 1.22%) stood among the top gainers.

₹6,424 per share. This uptick was followed by a report by CNBC-TV18 revealing the company's participation in the bidding process for Novartis AG's stake in Novartis India. The management of Dr.

rare earth minerals, electronics and pharmaceuticals as critical sectors to secure them against any future supply chain disruption. The move comes ahead of the Supply Chain Resilience Agreement of the 14-member Indo-Pacific Economic Framework (IPEF) entering into force next week. As per the agreement, the member countries have to identify critical sectors and key goods for cooperation upto 120 days after the date of the entry into force. The agreement will enter into force on February 24, 2024.

Also Read: Nifty 50, Sensex rise over 1% this week as focus shifts to fundamentals; Wipro, M&M, SBI shine The brokerage highlighted that the majority of sectors and stocks are overvalued. This overvaluation varies, with most large-cap consumers, IT services, and pharmaceuticals showing relatively low levels, the investment space displaying medium levels, and several low-quality companies reflecting high levels of overvaluation.

PM Modi retaining power after Lok Sabha elections. However, as investors are happy to overpay for weak business models in a few cases and unsustainably high profitability in others, there is only greed and no fear left in the market, said Sanjeev Prasad of Kotak Equities.

Dividend stocks: Shares of Oil and Natural Gas Corporation (ONGC), Emami, Torrent Power, Page Industries, JK Tyre & Industries, IRCON International, Sundaram Finance, Manappuram Finance, BEML, Siyaram Silk Mills, Dalmia Bharat Sugar and Industries, NLC India, JK Paper, Alkem Laboratories, Bajaj Consumer Care, Banco Products (India), Saven Technologies, Aarti Pharmalabs, Akzo Nobel India, Computer Age Management Services, Disa India, Firstsource Solutions, IOL Chemicals & Pharmaceuticals, J.B.Chemicals & Pharmaceuticals, Orient Cement, Shivalik Bimetal Controls, Triveni Turbine, Vidhi Specialty Food Ingredients, Mitsu Chem Plast, and Scanpoint Geomatics will be in focus when the stock market opens on February 16 (Friday). The Board of Directors of these companies have declared interim dividend and rights issue for their eligible shareholders.

By Medha Singh

Shares of AI-related names such as Arm, Recursion Pharmaceuticals (RXRX), and SoundHound AI (NASDAQ:SOUN) are rising premarket after it was revealed that a filing from NVIDIA (NVDA) disclosed stakes in the companies.

BSE on Thursday, February 15, a day after the company reported its December quarter earnings. Glenmark Pharma share price opened at ₹766.65 against the previous close of ₹796.30 and rose 6.4 per cent to the level of ₹847.30. Around 9:20 am, the stock traded 5.22 per cent up at ₹837.90.

Also Read-Glenmark Pharma share price jumps over 6% after Q3 result Bulk of the IPM growth in January 2024 was largely driven by therapies such as immunomodulators, hepatoprotectives, antivirals, cardiac and urology. However the softer growth rate in acute range is also attributed to high base and seasonal factors in January.

Pradyuman Reddy, Hyderabad, Telangana The Nifty Healthcare Index is a sectoral index on the NSE that captures the behaviour and performance of healthcare companies in the Indian economy on a real-time basis. It is constituted of 20 stocks that are listed on the NSE and are involved with the health and wellness industry. These include pharmaceuticals, hospitals, diagnostics, medical equipment, biotechnology, and other allied services.

Ashwini Agarwal, Founder, Demeter Advisors, says “I am quite excited by the whole chemical space where the earnings cycle seems to have bottomed out. I continue to believe in pharmaceuticals where I think the pricing environment and the demand environment are reasonably solid. I think IT services might be a place to hide. I do not own it personally. But from a risk return perspective in a benchmark portfolio and IT services holdings might do reasonably okay. I do not think a lot of absolute gain will be made there. But on a relative basis, they might hold up. I look at the stock price of Paytm, I look at the stock price of metals, I look at IT. I mean, there is bad news, there are bargains available. Ashwini Agarwal: Yes. There are bargains available for sure. If you look at the upstream chemical sector, after the peak of earnings in 2021, in the last one, one-and-a-half years you have seen a significant amount of decline in revenue and decline in margins led by inventory liquidation from the customers globally and you have seen a slowdown of demand as well. So, yes, there are bargains available.

Zenith Drugs IPO: The initial public offering (IPO) of small and medium-sized enterprises (SME) Zenith Drugs will be opening for subscription on Monday, February 19, 2024. It comprises a fresh issue with a price band set at ₹75 to ₹79 per share at a face value of ₹10 per share. The SME IPO will close on Thursday, February 22.

Shares of Zydus Lifesciences Ltd.(up 6.41 per cent), Dr. Reddy's Laboratories Ltd.(up 2.89 per cent), Divi's Laboratories Ltd.(up 2.41 per cent), Aurobindo Pharma Ltd.(up 1.55 per cent) and Abbott India Ltd.(up 1.41 per cent) ended the day as top gainers in the pack.

₹762 in February 2019 to around ₹6,500 currently. This implies a return of over 753 percent for its investors. Meanwhile, the stock has also given multibagger returns in the last 3 years as well as in the last 1 year.

BSE Sensex has dropped 1.5% year-to-date (YTD), while the Nifty 50 is down more than 0.4% since the beginning of 2024. The drop in the Indian stock market has been largely led by the outflow of foreign institutional investors’ (FII) money amid rising bond yields in the US. However, despite the volatility in the market, some penny stocks registered whopping gains so far this year.

Investing.com-- Shares of Australian pharmaceutical giant CSL Ltd (ASX:CSL) tumbled on Monday after it said that a phase 3 trial for a drug to treat second heart attacks had failed to meet its primary endpoint in efficacy.